The NM_000152.5:c.2132_2133delinsGG variant in GAA is a multinucleotide variant predicted to cause substitution of threonine by arginine at amino acid 711 (p.Thr711Arg). The same amino acid change, resulting from one of the two nucleotide changes observed in this multinucleotide variant, c.2132C>G, has been reported in a patient with Pompe disease (PMID: 20080426, 31342611). However, this other variant has conflicting evidence for pathogenicity based on guidelines by the ClinGen LSD VCEP (PMID: 18425781). The minor allele frequency of the c.2132C>G variant in gnomAD v2.1.1 is 0.001258 (23/18290 alleles) in the East Asian population, but was only seen in phase with c.2133A>G in 23 of the 24 heterozygotes reported in gnomAD v2.1.1. Therefore, the highest possible population minor allele frequency in gnomAD v2.1.1 is 0.001258 (23/18290 alleles) in the East Asian population (none of the population data codes are met). The computational predictors PROVEAN, Mutation Taster, and MutPredIndel suggest that this variant has a deleterious effect on the GAA gene, evidence that correlates with impact to GAA function (PP3). To our knowledge, the results of functional assays have not been reported for this variant. There is a ClinVar entry for this variant (Variation ID: 456391, 1 star review status) with 2 submitters, 1 submitter classifying the variant as likely pathogenic and 1 submitter classifying the variant as a variant of uncertain significance. In summary, this variant meets the criteria to be classified as a variant of uncertain significance for Pompe disease based on the ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Storage Disorders Variant Curation Expert panel (specifications Version 2.0): PP3.